Literature DB >> 21996066

UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.

Xavier Delavenne1, Julie Moracchini, Silvy Laporte, Patrick Mismetti, Thierry Basset.   

Abstract

This article described the development and full validation of rapid and accurate liquid chromatography method, coupled with tandem mass spectrometry detection, for quantification of dabigatran in human plasma with [(13)C(6)]-dabigatran as internal standard. Plasma pretreatment involved a single step protein precipitation with methanol. Separation was performed by ultra performance reversed-phase chromatography on an Acquity UPLC BEH C8 100 mm × 1 mm × 1.7 μm column using a gradient elution mode. The mobile phase was a mix of distilled water containing 0.1% formic acid and methanol containing 0.1% formic acid. Specific multiple reaction monitoring transitions were recorded in positive electrospray ionization. The method was linear over the concentration range of 2-500 μg/L. The intra- and inter-day precision values were below 11.3% and accuracy was within 93.8% and 108.8% for all QC levels (5, 75 and 400 μg/L). The lower limit of quantification was 2 μg/L. Total analysis time was to 10 min including sample preparation.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996066     DOI: 10.1016/j.jpba.2011.09.018

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  10 in total

Review 1.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Bethany T Samuelson; Adam Cuker; Deborah M Siegal; Mark Crowther; David A Garcia
Journal:  Chest       Date:  2016-09-13       Impact factor: 9.410

2.  Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran.

Authors:  Paul K L Chin; David M Patterson; Mei Zhang; Berit P Jensen; Daniel F B Wright; Murray L Barclay; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

3.  Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism.

Authors:  Zhe-Yi Hu; Robert B Parker; Vanessa L Herring; S Casey Laizure
Journal:  Anal Bioanal Chem       Date:  2012-12-14       Impact factor: 4.142

4.  Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.

Authors:  Paul K L Chin; Daniel F B Wright; Mei Zhang; Mary C Wallace; Rebecca L Roberts; David M Patterson; Berit P Jensen; Murray L Barclay; Evan J Begg
Journal:  Drugs R D       Date:  2014-06

5.  A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.

Authors:  Xavier Delavenne; Edouard Ollier; Thierry Basset; Laurent Bertoletti; Sandrine Accassat; Arnauld Garcin; Silvy Laporte; Paul Zufferey; Patrick Mismetti
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

Review 6.  A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.

Authors:  Paul K L Chin; Daniel F B Wright; David M Patterson; Matthew P Doogue; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

7.  Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.

Authors:  Luigi Brunetti; Betty Sanchez-Catanese; Leonid Kagan; Xia Wen; Min Liu; Brian Buckley; James P Luyendyk; Lauren M Aleksunes
Journal:  Thromb J       Date:  2016-05-06

8.  UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

Authors:  Joachim Kuhn; Tatjana Gripp; Tobias Flieder; Marcus Dittrich; Doris Hendig; Jessica Busse; Cornelius Knabbe; Ingvild Birschmann
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

9.  Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-03

10.  Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.

Authors:  L Slavik; J Jacova; D Friedecky; J Ulehlova; Z Tauber; J Prochazkova; A Hlusi; M Palova
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.